Cash-pay GLP-1 access: what patients are actually comparing

Branded drugs with manufacturer savings programs, compounded options facing new FDA scrutiny, and telehealth cash-pay programs all look different on paper. Here's how to read the full picture before you commit.

Cash-pay GLP-1 access generally falls into three main categories: 1. Branded drugs through manufacturer savings programs — FDA-approved medications like Zepbound (tirzepatide) or Wegovy (semaglutide), offered at reduced cash prices through programs run by the drug's manufacturer. 2. Compounded semaglutide or tirzepatide — drugs prepared by compounding pharmacies, often sold through telehealth platforms, that are not FDA-approved and are now facing active regulatory scrutiny. 3. Telehealth cash-pay programs that dispense FDA-approved branded drugs — programs that bundle a prescriber visit, ongoing check-ins, and an FDA-approved medication into a single monthly price. Each category carries different costs, different regulatory standing, and different risks. The lowest sticker price is rarely the complete cost, whether measured in money, in oversight, or in peace of mind.

Zepbound (tirzepatide)

Eli Lilly offers a cash-pay option through its Zepbound Journey Program, with pricing starting at $299 per month for patients without insurance coverage. That is a substantial reduction from the drug's list price, and it covers an FDA-approved medication dispensed through licensed pharmacies. A few caveats apply. The program has eligibility conditions, including insurance status, that determine whether you qualify. Not everyone will. Introductory doses and maintenance doses are also often priced differently, so confirm what your target dose will cost, not just your starting dose. And manufacturer savings programs are not permanent entitlements. Terms, pricing, and availability can be modified or discontinued without advance notice. Before counting on this program, verify your eligibility and current pricing directly with Lilly at the official Zepbound website.

Wegovy (semaglutide)

Novo Nordisk's NovoCare program has offered savings options for uninsured patients seeking Wegovy. The current details of this program, including eligibility, pricing, and availability, could not be independently verified at the time this article was written, and the terms may have changed. If you're considering Wegovy through a manufacturer savings program, contact NovoCare directly to confirm what is currently available and whether you qualify.

What to verify before counting on any manufacturer program

Before enrolling, confirm whether you're currently eligible based on your insurance status, whether the program covers the dose you're likely to need at maintenance rather than just the starting dose, whether the program is currently active, and what happens to your access if the terms change or the program ends.

What compounding is, and why it became an option

Compounding pharmacies prepare customized medications, typically for patients with specific needs that commercially available drugs don't meet. During periods when FDA-approved GLP-1 medications were in shortage, federal law permitted compounding pharmacies to produce versions of those drugs, and many telehealth companies began offering them as a lower-cost alternative. That legal window has narrowed significantly.

Where things stand now

The FDA has declared the shortages of both semaglutide and tirzepatide resolved. That declaration matters because it triggers the agency's enforcement authority over compounded versions of those drugs. In March 2026, the FDA issued warning letters to approximately 30 telehealth companies for making false or misleading claims about compounded GLP-1 products. The agency has also stated its intent to take action against non-FDA-approved GLP-1 drugs marketed by telehealth companies and compounding pharmacies. This is an actively evolving situation. Court challenges and regulatory decisions may continue to shift what is legally available in different states. This article cannot confirm which specific compounders or telehealth platforms are currently operating in compliance, as that status changes frequently. Patients should verify directly with regulators and their own clinician.

What "not FDA-approved" means in practice

Compounded drugs do not undergo FDA review for safety, effectiveness, or quality. That's not a technicality. It means there is no independent verification that a compounded product contains what the label says it contains, in the amount stated, prepared under conditions that preserve its integrity. The FDA has documented specific concerns about compounded GLP-1 products, including reported adverse events (among them dosing errors) associated with compounded injectable semaglutide, and potential quality risks from improper storage during shipping. The agency also explicitly prohibits claims that a compounded GLP-1 product is the "same" as an FDA-approved branded drug. Compounded drugs are not equivalent, legally or regulatorily, even if they contain a similar active ingredient.

What patients should understand right now

If you are currently using or considering a compounded GLP-1 product, ask the provider: What specific form and salt of the drug is being used? Where is it compounded, and is that pharmacy licensed in your state? What is the current regulatory status of the product you're being offered? And who do you contact if something goes wrong? A legitimate provider should be able to answer all of these questions directly.

Telehealth programs that offer GLP-1 medications vary widely in what they include and what they don't. Understanding the difference between a bundled and an unbundled model matters before you sign up. A program may include an initial prescriber visit (often asynchronous, meaning you fill out a form rather than speaking live with a clinician), a prescription for an FDA-approved or compounded GLP-1 medication, ongoing check-ins that may be automated or clinician-led, and titration guidance as your dose increases. What a program may not include is equally important: lab work such as baseline metabolic panels, A1c, thyroid screening, or ongoing monitoring; in-person care or referrals if you develop complications; meaningful support for managing side effects like nausea, vomiting, or GI distress; or a clear path to transition to an in-person provider if your needs change.

The introductory dose problem

Many telehealth programs advertise a monthly price that reflects the starting dose of a GLP-1 medication. Starting doses are lower and cheaper than the maintenance doses most patients eventually reach. If you're comparing programs based on advertised prices, confirm what you'll pay at the dose you're likely to be on six months from now, not the dose you'll start at.

What to ask before enrolling

Before signing up, get clear answers on the price at each dose level including the maintenance dose, whether follow-up visits are included or billed separately, who orders and pays for lab work, what happens if you have a side effect and need clinical support, whether you can transfer your records to an in-person provider, and whether the medication being dispensed is FDA-approved and the pharmacy is licensed in your state.

Medication cost

Look beyond the starting price. What does the program cost at the dose you're likely to need for ongoing treatment? What happens if you need a dose adjustment, up or down?

Prescriber and monitoring visits

Are follow-up visits included in the monthly fee, or billed separately? How often are they expected, and what do they involve?

Lab work

GLP-1 therapy typically involves baseline labs and periodic monitoring. Who orders those labs in the program you're considering? Who pays for them? If the program doesn't address this, that cost falls to you, and it's not small.

Side effect management

GLP-1 medications commonly cause nausea, vomiting, and other GI symptoms, particularly during dose escalation. What support does the program offer if you're struggling? Is there a clinician you can reach, or only an automated system?

Continuity of care

If you need to transition to in-person care, because of a side effect, a change in your health, or a move, will your records transfer? Is there a clear process for that, or will you be starting over?

Program stability

What happens if the program changes its pricing, changes its formulary, or closes? This is not a hypothetical concern in a market that has changed rapidly.

Regulatory standing of the medication

Is the drug FDA-approved? Is the dispensing pharmacy licensed in your state? If the medication is compounded, what is its current regulatory status?

The questions in the previous section are ones you can research on your own. A clinician conversation adds something different: an assessment of your specific health profile and whether a given program is adequate for it. Before committing to any cash-pay GLP-1 program, consider discussing the following with a clinician who knows your history.

Whether you're a candidate for GLP-1 therapy at all

These medications have contraindications, including a personal or family history of certain thyroid cancers and pancreatitis, that need to be evaluated before starting.

Which drug and dose is appropriate for your situation

Not all GLP-1 medications are interchangeable, and the right choice depends on your health profile and goals.

What monitoring your individual situation requires

Some patients need more frequent or more specific lab monitoring than others. A clinician can help you understand what's appropriate for you and whether a given program provides it.

How to evaluate clinical oversight in a telehealth program

A clinician can help you assess whether the level of oversight a program offers is adequate for your needs.

If you're considering a compounded product, ask specifically what salt or form of the drug is being used, where it is compounded, and what the current regulatory status is. These are reasonable questions that a legitimate provider should be able to answer.

Whether the manufacturer savings programs you're considering are currently active, and whether you qualify

A clinician or their staff may be able to help you navigate this.

This article reflects information available at the time of writing. Several things are genuinely uncertain or subject to change. Manufacturer savings program terms change. Eligibility, pricing, and availability for both the Zepbound Journey Program and NovoCare's Wegovy savings program should be verified directly with Lilly and Novo Nordisk. The NovoCare program details could not be independently confirmed for this article. The regulatory situation for compounded GLP-1s is actively evolving. Enforcement actions, court decisions, and state-level regulatory activity may shift what is legally available. What is true today may not be true in three months. Telehealth program pricing is not standardized and was not independently verified for this article. Prices, services, and terms vary significantly by provider. This article does not endorse or evaluate any specific telehealth platform or compounding pharmacy. Individual cost comparisons depend heavily on dose, health profile, and geography. A framework for comparison is useful; a personalized calculation requires personalized information.